Clinical trial Recruiting at 1 site Interventional Ages 50 and up Men only

Water Vapor Therapy vs Ejaculation-Sparing Enucleation for Benign Prostatic Hyperplasia

Official title: Water Vapor Thermal Therapy Versus Ejaculation-Sparing Bipolar Transurethral Enucleation of the Prostate for Benign Prostatic Hyperplasia: A Prospective Comparative Study

Run by Beni-Suef University · NCT07648888 · Data updated 2026-11-12

This study tests whether Water Vapor Thermal Therapy (Rezum) or an ejaculation-sparing enucleation procedure better helps sexually active men with bothersome BPH symptoms.

Quick facts

Study typeInterventional
Ages50 Years and up
SexMen only
Enrollment120 (estimated)
SponsorBeni-Suef University
Academic / other
Locations1 site (Banī Suwayf, Beni Suweif Governorate)
StatusRecruiting
StartedJune 8, 2026
Main results expectedNovember 2027
Study endsDecember 2027
Registry record updatedJune 15, 2026
Trial IDNCT07648888 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Sexually active men aged 50 or older with moderate-to-severe LUTS, IPSS ≥13, prostate 30–80 mL, Qmax ≤15 mL/s, PVR ≤250 mL, and preserved antegrade ejaculation who have failed or unwilling to continue medical therapy.

Probably not a fit

Patients who do not experience meaningful urinary improvement or who have outcomes limited by anatomical or comorbidity factors may not perceive benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, non-randomized study compares two procedural treatments for men over 50 with moderate-to-severe lower urinary tract symptoms due to BPH who wish to preserve ejaculation. Participants choose between Water Vapor Thermal Therapy and an ejaculation-sparing bipolar enucleation after counseling. Outcomes include urinary symptom relief, urinary flow, residual urine, erectile function, perioperative data, complications, catheterization duration, hospital stay, need for medications, and retreatment over follow-up. The trial is not randomized and uses shared decision-making to assign treatment within two cohorts. The primary outcome focuses on the rate of treatment success or improvement in relevant clinical endpoints.

Why it matters

Potential benefit: If successful, the study could clarify which ejaculation-sparing option provides better symptom relief while preserving ejaculation in men with BPH.

How similar studies have gone: Prior studies with similar ejaculation-preserving approaches have shown promising but variable outcomes; this specific head-to-head comparison is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Male patients aged 50 years or older.
* Symptomatic benign prostatic hyperplasia with moderate-to-severe lower urinary tract symptoms.
* International Prostate Symptom Score (IPSS) 13 or higher.
* Prostate volume 30 to 80 mL measured by transrectal ultrasound.
* Maximum urinary flow rate (Qmax) 15 mL/s or less with voided volume 150 mL or more.
* Post-void residual urine volume 250 mL or less.
* Failed, intolerant, or unwilling to continue medical therapy for benign prostatic hyperplasia.
* Sexually active within the previous 3 months.
* Preserved antegrade ejaculation at baseline.
* Patient wishes to preserve ejaculation.
* Ability to complete the International Prostate Symptom Score (IPSS), International Index of Erectile Function-5 (IIEF-5), and Male Sexual Health Questionnaire-Ejaculatory Dysfunction Short Form (MSHQ-EjD-SF).
* Written informed consent.

Exclusion Criteria:

* Suspected or confirmed prostate cancer.
* Abnormal prostate-specific antigen or digital rectal examination suspicious for malignancy unless prostate cancer has been excluded according to standard clinical practice.
* Previous prostate surgery.
* Previous urethral surgery likely to affect instrumentation or study outcomes.
* Urethral stricture disease.
* Neurogenic bladder dysfunction.
* Active urinary tract infection until adequately treated.
* Bladder stones requiring concomitant surgery.
* Prostate volume less than 30 mL or more than 80 mL.
* Baseline anejaculation or severe ejaculatory dysfunction.
* No sexual activity during the previous 3 months.
* Chronic indwelling urethral or suprapubic catheter.
* Recurrent urinary retention or suspected detrusor underactivity requiring urodynamic clarification.
* Post-void residual urine volume more than 250 mL.
* Uncontrolled coagulopathy.
* Anticoagulation or antiplatelet therapy that cannot be safely managed perioperatively.
* Unfitness for anesthesia or intervention.
* Inability or unwillingness to comply with follow-up.

Where it's running

  • Department of Urology- Beni-Suef University Hospitals
    Banī Suwayf, Beni Suweif Governorate, Egypt
    Recruiting

Study contacts

  • Principal investigator: Hany F Badawy, MD — Faculty of Medicine, Beni-Suef University hospital
  • Study coordinator: Hany F Badawy, MD
  • Email: HANYFATHY86@GMAIL.COM
  • Phone: +201149525028

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.